AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02628223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neodymium:Yttrium Aluminum Garnet (YAG) laser
Description: The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
Study NCT02214758 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition and oral health interventions
Description: On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.
Study NCT00865501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spironolactone
Description: 25mg per oral once daily
Study NCT00865501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03419247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood will be taken by a needle from a vein.
Study NCT03419247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Archival tumor tissue collection
Description: A sample of tumor tissue that was taken by biopsy or surgery before agreeing to take part in this study will be collected.
Study NCT01791062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYTOP®
Description: HYTOP® will be implanted once during surgery.
Study NCT02729987 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WorkGuru
Description: A multi-modal stress management intervention accessed over 8 weeks, incorporates CBT, positive psychology and Mindfulness. Delivered via the internet.
Study NCT04005222 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SELENIUM
Description: Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium supplementation.
Study NCT04005222 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MELATONIN
Description: Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.
Study NCT05291195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-device group
Description: After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the laser-device groups, the adjuvant treatment approaches were performed either by means of photodynamic therapy (HELBO, Photodynamic Systems GmbH) or high power diode laser (940nm, Biolase ® Technology, CA, USA). Performing photodynamic therapy the root canals were filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Germany) for 2 min following irradiation of diode laser (HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW)) for 60 s. Performing only diode laser the root canals were be irrigated with a diode laser (λ = 940 maximal power 10W) for 60 s.
Study NCT05291195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential Oil
Description: After each instrumentation, the root canals were irrigated with 1.5 % sodium hypochlorite (NaOCl).~Depending on allocations, in the EO group, the adjuvant treatment approaches were performed either by means of essential oil (Cymbopogon martinii and Thymus vulgaris, Herba oils, Herba d.o.o, Belgrade, Serbia)
Study NCT05291195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite group
Description: Mechanico-chemical root canal preparation and root canal disinfection were be performed by means of mechanic-chemical methods including hand instruments followed by 1.5% sodium hypochlorite (pH 12), at room temperature (21 degrees Celsius).
Study NCT02235922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task training
Description: The dual task training consisted of individuals subjected to a multicomponent exercise program associated to cognitive tasks.
Study NCT02235922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional training
Description: The conventional training consisted of individuals subjected to a multicomponent exercise program.
Study NCT01289535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample of 7 ml
Study NCT01812746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIND-014
Study NCT02213991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy using Intrabeam®
Description: Operation day~1. Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity.~2. Purse string suture pulles up tissues and wraps up the applicator.~3. Intraoperative radiotherapy using Intrabeam® (20Gy) is followed.~4. After IORT, applicator was out of the operative field, and usual wound closure will be done.~   * Postoperative period~     * Chemotherapy WBRT (46 Gy) for 4\~5 weeks~    * Endocrine therapy or target therapy
Study NCT03357445 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Avantage Reload cup
Description: Patients receiving the Avantage Reload acetabular cup in total hip arthroplasty
Study NCT01857115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Study NCT01857115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT03375957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATx201
Description: two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms
Study NCT03375957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATx201 Placebo Gel
Description: two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms
Study NCT02287844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: XOS
Description: 5 g of XOS everyday for 4 weeks.
Study NCT02287844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INU-XOS
Description: 1 g of XOS and 3 g of inulin everyday for 4 weeks.
Study NCT01857115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT04414202 — intervention group
Intervention type: PROCEDURE
Intervention: tumorectomy with axillary dissection (sentinel lymph node)
Description: All patients will have local excision of the primary tumor following appropriate clinical work-up. Surgery will be done according to usual local practice with a complete excision of the tumor. The aim of the local excision should be to achieve a minimum free margin of 2 mm whilst maintaining a good cosmetic outcome.
Study NCT04414202 — intervention group
Intervention type: RADIATION
Intervention: per-operative partial irradiation
Description: 20 Gy of per-operative partial irradiation at the tumor site during the surgery
Study NCT02287844 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 6.64 g of maltodextrins everyday for 4 weeks.
Study NCT02726360 — intervention group
Intervention type: BEHAVIORAL
Intervention: survey
Description: The ILR Scale, a non-English language proficiency self-assessment.
Study NCT02415218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mucosal cell sheet transplantation
Description: The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
Study NCT02475213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: enoblituzumab is administered by IV infusion once per week for up to 51 doses.
Study NCT02726360 — intervention group
Intervention type: BEHAVIORAL
Intervention: Audio record
Description: Audio record the initial visits between patients and their treating physician
Study NCT02240628 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine/tetracaine transdermal patch
Description: All patients in arm 1 and arm 2 will receive the Synera Patch.
Study NCT02240628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine/tetracaine transdermal patch
Description: All patients in arm 1 and arm 2 will receive the Synera Patch.
Study NCT02240628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients in arm 2 will receive Saline with the Propofol.
Study NCT02240628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients in arm 1 will receive Lidocaine with the Propofol.
Study NCT03121716 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
Study NCT03121716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine
Study NCT03121716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cis-platinum
Description: cis-platinum
Study NCT00318188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standardized reeducation and readaptation program
Study NCT01408654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Companionship
Description: Peer companionship is provided at least four times per month over two years in the form of friendly visiting, supportive phone calls, and some instrumental support.
Study NCT04029545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PN40082
Description: 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
Study NCT04029545 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PN40082
Description: 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
Study NCT01963663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 1000 mg daily in two divided doses of 500 mg tablets
Study NCT02410369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-588410
Description: Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
Study NCT02410369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following randomization, subjects with HLA-A\*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
Study NCT03450889 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Patients will undergo surveillance colonoscopies, with intervals of 1 or 2 years depending on the amount and type of polyps resected during last colonoscopy.~In case patients underwent subtotal colectomy, the term 'colonoscopy' should be replaced with 'sigmoidoscopy'.
Study NCT02717546 — intervention group
Intervention type: DEVICE
Intervention: Zimmer MotionLoc Screw
Description: Patients with distal tibia fractures (AO 43-A and C) requiring surgical intervention eligible for locked plating.
Study NCT00974779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCO1100 dialyzer
Description: Thrice weekly dialysis using the HCO1100 dialyzer for 4.5h, 2 weeks
Study NCT00974779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: regular dialysis polyamide
Description: Continuation of the regular hemodialysis using polyamide high-flux hemodialysers
Study NCT03117933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablet, 100mg and 150mg
Study NCT03117933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Tablet 15mg and 20mg
Study NCT03117933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous (IV)
Study NCT01237548 — intervention group
Intervention type: OTHER
Intervention: Smoking Narghile for 30 min
Description: No Other intervention will be used
Study NCT04116034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alfapump DSR system
Description: Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
Study NCT05712031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of 1 Nucleoss T4 dental implants in posterior mandible
Description: Nucleoss T4 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
Study NCT05712031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of 1 Nucleoss T5 dental implants in posterior mandible
Description: Nucleoss T5 dental implants is combined with first or second premolar to support 3 unit fixed partial dentures
Study NCT05712031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of 2 Nucleoss T4 dental implants posterior mandible
Description: 2 freestanding Nucleoss T4 dental implants is used to support 3 unit fixed partial dentures
Study NCT05090345 — intervention group
Intervention type: OTHER
Intervention: Biorepository Trial
Description: participating in this arm, peripheral blood specimen(s) will be obtained at 8 specified time-points.
Study NCT04095416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACE compression wrap
Description: Bilateral lower extremity ACE compression wraps
Study NCT00816972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine 2.5 mg
Description: Desloratadine 2.5 mg BID
Study NCT00816972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 2.5 mg
Description: Desloratadine 2.5 mg BID
Study NCT00816972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin 2.5 mg
Description: Oxybutynin 2.5 mg BID
Study NCT00816972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin 2.5 mg
Description: Oxybutynin 2.5 mg BID
Study NCT00816972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Desloratadine 2.5 mg
Description: Placebo BID
Study NCT00816972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Desloratadine 2.5 mg
Description: Placebo BID
Study NCT00816972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Oxybutynin 2.5 mg
Description: Placebo BID
Study NCT00816972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Oxybutynin 2.5 mg
Description: Placebo BID
Study NCT00816972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Oxybutynin 2.5 mg
Description: Placebo BID
Study NCT03763279 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Triclosan-coated barbed suture
Description: Use of Triclosan-coated Polydioxanone barbed suture
Study NCT03763279 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Triclosan-coated monofilament suture
Description: Use of Triclosan-coated Polydioxanone monofilament suture
Study NCT03763279 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Monofilament suture
Description: Use of Polydioxanone monofilament suture
Study NCT00609128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olopatadine
Description: olopatadine one drop in one eye for one week
Study NCT00994565 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitoring and distance counseling
Description: The physical activity monitoring and distance counseling concept combines the use of a personal activity monitor with web-based tailored physical activity advice. Users can interactively plan and evaluate their own activity advice based on their actual PA scores and their PA preferences and goals.
Study NCT02640612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501
Study NCT01737164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Study NCT00768638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
Study NCT00768638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
Study NCT03461679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block
Description: Single shot block with 0.5% bupivacaine 10mls
Study NCT03461679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral triangle block
Description: Single shot block with 0.5% bupivacaine 10mls
Study NCT03461679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral triangle block
Description: Single shot block with 0.5% bupivacaine 10mls
Study NCT02692261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Sinus Augmentation
Description: Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution
Study NCT02692261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary Sinus Augmentation
Description: Control group sinuses filled with heterolog bone graft alone
Study NCT04626310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy - emotion regulation skills training
Description: Arm 1. Dialectical behavior therapy - emotion regulation skills training follows the emotion regulation skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.~Arm 2. Dialectical behavior therapy - interpersonal effectiveness skills training follows the interpersonal effectiveness skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.
Study NCT04626310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy - interpersonal effectiveness skills training
Description: Arm 2. Dialectical behavior therapy - interpersonal effectiveness skills training follows the interpersonal effectiveness skills DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition. This group involves 6 weekly sessions.
Study NCT04626310 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal psychotherapy
Description: Arm 3. Non-skills-oriented interpersonal psychotherapy group follows evidence-based principles on common factors in a group therapy context. This group involves 6 weekly sessions.
Study NCT02397564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser, traditional and fractional settings
Description: Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
Study NCT01963663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: pioglitazone 30 mg daily in two divided doses of 15 mg tablets
Study NCT01756807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The COMBO Stent
Description: The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
Study NCT03277963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pain perception tests (mechanical : VON FREY ELECTRONIQUE or electrical stimulus : PAIN MATCHER®)
Description: From a basal level causing no particular sensation, the mechanical or electrical stimulus is applied with a constant increasing rate of progression.
Study NCT03277963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain perception tests (mechanical : VON FREY ELECTRONIQUE or electrical stimulus : PAIN MATCHER®)
Description: From a basal level causing no particular sensation, the mechanical or electrical stimulus is applied with a constant increasing rate of progression.
Study NCT02539628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine 0.2%
Description: Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
Study NCT02539628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2%
Description: Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
Study NCT02901028 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Laboratory testing
Description: Subjects will visit the Human Performance Laboratory on two separate occasions to perform the testing procedures. testing consists of VO2, strength, biomechanics, dynavision, etc.